{"id":"placebo-plus-metformin-ir","safety":{"commonSideEffects":[{"rate":"10-30","effect":"Gastrointestinal disturbance (nausea, diarrhea, abdominal discomfort)"},{"rate":"3-10","effect":"Metallic taste"},{"rate":"10-30","effect":"Vitamin B12 deficiency"},{"rate":"<0.1","effect":"Lactic acidosis (rare)"}]},"_chembl":{"chemblId":"CHEMBL1431","moleculeType":"Small molecule","molecularWeight":"129.17"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Metformin IR (immediate-release) is a biguanide that decreases gluconeogenesis in the liver and enhances peripheral glucose uptake and utilization. In this phase 3 trial design, placebo is combined with metformin IR as the control or reference arm to evaluate efficacy and safety outcomes in a diabetes population.","oneSentence":"Metformin reduces hepatic glucose production and improves insulin sensitivity, while placebo serves as a control comparator in this combination study.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:28:19.859Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 2 diabetes mellitus"}]},"trialDetails":[{"nctId":"NCT06042855","phase":"PHASE3","title":"ACTIV-6: COVID-19 Study of Repurposed Medications - Arm G (Metformin)","status":"COMPLETED","sponsor":"Susanna Naggie, MD","startDate":"2023-09-05","conditions":"Covid19","enrollment":3214},{"nctId":"NCT04885530","phase":"PHASE3","title":"ACTIV-6: COVID-19 Study of Repurposed Medications","status":"COMPLETED","sponsor":"Susanna Naggie, MD","startDate":"2021-06-08","conditions":"Covid19","enrollment":10956},{"nctId":"NCT03507413","phase":"PHASE2, PHASE3","title":"Metformin Therapy in Non-diabetic AAA Patients","status":"ACTIVE_NOT_RECRUITING","sponsor":"Medical University of Vienna","startDate":"2018-09-26","conditions":"Abdominal Aortic Aneurysm","enrollment":170},{"nctId":"NCT04854512","phase":"PHASE3","title":"Investigational Study of Delayed Release Metformin","status":"SUSPENDED","sponsor":"Anji Pharma","startDate":"2021-05-18","conditions":"Diabetes Mellitus, Type 2","enrollment":675},{"nctId":"NCT02491333","phase":"PHASE3","title":"The RCT of Acupuncture on PCOS Combined With IR","status":"COMPLETED","sponsor":"The First Affiliated Hospital of Guangzhou Medical University","startDate":"2015-08","conditions":"Polycystic Ovary Syndrome, Insulin Resistance","enrollment":342},{"nctId":"NCT01864174","phase":"PHASE4","title":"Phase 4: Investigational Study to Evaluate Metformin XR Monotherapy Versus Metformin IR Monotherapy in Subjects With Type 2 Diabetes","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2013-06-20","conditions":"Type 2 Diabetes Mellitus","enrollment":1736},{"nctId":"NCT02791490","phase":"PHASE3","title":"A Study of the Safety and Efficacy of Sitagliptin Addition During Metformin Up-titration (MK-0431-848)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2016-06-16","conditions":"Type 2 Diabetes Mellitus","enrollment":458},{"nctId":"NCT02492763","phase":"PHASE2","title":"A Preliminary Study of the Efficacy and Safety of MK-8521 for Type 2 Diabetes (MK-8521-004)","status":"TERMINATED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2015-07-27","conditions":"Type II Diabetes Mellitus","enrollment":176},{"nctId":"NCT02526524","phase":"PHASE2","title":"Dose-Ranging Study to Evaluate the Glycemic Effects, Safety, and Tolerability of Metformin Delayed Release in Subjects With T2DM","status":"COMPLETED","sponsor":"Elcelyx Therapeutics, Inc.","startDate":"2015-09","conditions":"Type 2 Diabetes Mellitus","enrollment":571},{"nctId":"NCT02273050","phase":"PHASE3","title":"Evaluate the Efficacy and Safety of Saxagliptin in Combination With Metformin IR Compared to Saxagliptin Monotherapy and to Metformin IR Monotherapy in Drug Naive Chinese Subjects With Type 2 Diabetes Who Have Inadequate Glycaemic Control","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2014-12","conditions":"Type 2 Diabetes Mellitus","enrollment":1136},{"nctId":"NCT03061981","phase":"PHASE1","title":"A Study To Evaluate The Safety,Tolerability, PK and PD Of DA-1241 In Healthy Male Subjects","status":"COMPLETED","sponsor":"Dong-A ST Co., Ltd.","startDate":"2017-03-29","conditions":"Diabetes Mellitus, Type 2","enrollment":60},{"nctId":"NCT01204775","phase":"PHASE3","title":"Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of Saxagliptin as Monotherapy in Pediatric Patients With Type 2 Diabetes","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2011-06","conditions":"Type 2 Diabetes","enrollment":26},{"nctId":"NCT01434186","phase":"PHASE3","title":"A Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Saxagliptin (BMS-477118) in Combination With Metformin IR or Metformin XR in Pediatric Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control on Metformin Alone","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2012-05","conditions":"Diabetes Mellitus, Type 2","enrollment":32},{"nctId":"NCT01646320","phase":"PHASE3","title":"Safety and Efficacy of Dapagliflozin in Triple Therapy to Treat Subjects With Type 2 Diabetes","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2012-09","conditions":"Type 2 Diabetes","enrollment":320},{"nctId":"NCT01619059","phase":"PHASE3","title":"Safety and Efficacy of Saxagliptin in Triple Therapy to Treat Subjects With Type 2 Diabetes","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2012-06","conditions":"Type 2 Diabetes","enrollment":315},{"nctId":"NCT01065298","phase":"","title":"Efficacy Of Autologous Bone Marrow Derived Stem Cell Transplantation In Patients With Type 2 Diabetes Mellitus-2","status":"COMPLETED","sponsor":"Post Graduate Institute of Medical Education and Research, Chandigarh","startDate":"2009-11","conditions":"Type 2 Diabetes Mellitus","enrollment":30},{"nctId":"NCT00885378","phase":"PHASE3","title":"Efficacy and Safety Study of Saxagliptin + Metformin Immediate Release (IR) Versus Metformin IR Alone in Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2009-05","conditions":"Type 2 Diabetes Mellitus","enrollment":166},{"nctId":"NCT00327015","phase":"PHASE3","title":"A Phase 3 Study of BMS-477118 in Combination With Metformin in Subjects With Type 2 Diabetes Who Are Not Controlled With Diet and Exercise","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2006-05","conditions":"Diabetes","enrollment":1306},{"nctId":"NCT01217892","phase":"PHASE3","title":"Evaluation of Dapagliflozin Taken Twice-daily","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2010-11","conditions":"Type 2 Diabetes","enrollment":400},{"nctId":"NCT01106677","phase":"PHASE3","title":"The CANTATA-D Trial (CANagliflozin Treatment and Trial Analysis - DPP-4 Inhibitor Comparator Trial)","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2010-05","conditions":"Diabetes Mellitus, Type 2","enrollment":1284}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Placebo plus metformin IR","genericName":"Placebo plus metformin IR","companyName":"AstraZeneca","companyId":"astrazeneca","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Metformin reduces hepatic glucose production and improves insulin sensitivity, while placebo serves as a control comparator in this combination study. Used for Type 2 diabetes mellitus.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}